Polymorphs and salts
The present invention is directed to novel polymorphs and salts of a compound which is an inhibitor of kinase activity.
1. A polymorph (Form II) of N-[5-[4-(5-{[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl}-1,3-oxazol-2-yl)-1H-indazol-6-yl]-2-(methyloxy)-3-pyridinyl]methanesulfonamide characterised in that it provides an XRPD pattern comprising a peak at (°2θ) 9.2+/−0.1.
2. A polymorph according to claim 1 characterised in that it provides an XRPD pattern comprising peaks substantially as set out in Table 1.
3. A polymorph according to claim 1 in that it provides an XRPD pattern substantially in accordance with FIG. 1 .
4. A pharmaceutical composition comprising a polymorph as defined in claim 1 and one or more pharmaceutically acceptable excipients.